The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Proton beam therapy in lung cancer with interstitial lung disease
Crispin Hiley, MBChB, PhD, University College London, London, UK, summarizes the initial UK experience of proton beam therapy (PBT) for patients with lung cancer and interstitial lung disease (ILD), a population at high risk of treatment-related toxicities. PBT achieved effective target coverage while substantially limiting radiation exposure to normal tissues. Among the first treated patients, only mild toxicities were observed, with no severe events. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so the UK now has two really world-class, world-leading proton beam radiotherapy centres, one in Manchester at Christie Hospital and one in London at UCLH Hospital where I work. And what we’ve been fortunate enough to be able to do is to help patients with interstitial lung disease, who then go on to get a diagnosis of lung cancer. Those are patients where there’s a high risk of exacerbating their interstitial lung disease with surgery, with immunotherapy, with radiotherapy...
Yes, so the UK now has two really world-class, world-leading proton beam radiotherapy centres, one in Manchester at Christie Hospital and one in London at UCLH Hospital where I work. And what we’ve been fortunate enough to be able to do is to help patients with interstitial lung disease, who then go on to get a diagnosis of lung cancer. Those are patients where there’s a high risk of exacerbating their interstitial lung disease with surgery, with immunotherapy, with radiotherapy. And so often they’re patients who end up quite often having no treatment at all. And so what we’ve been fortunate enough in the UK to do is to be able to start to offer proton beam radiotherapy on a case-by-case basis for patients with locally advanced disease in the context of interstitial lung disease. And what we show from this initial experience of a few patients is, again, really very low doses to the surrounding lung. And so far, no serious acute side effects. And we continue to follow those patients up. And I think on a case-by-case basis for patients with interstitial lung disease and lung cancer, protons for patients with advanced disease, but also MR-guided stereotactic radiotherapy for patients with early disease, are things that we can use to reduce the risk of side effects from radiotherapy in those patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
